Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lissoni

Showing results (1-10 of 287) with videos related to

Pageof 29
Sort By:
Pathologie-Biologie|April 25, 2007
Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agentP Lissoni
Cancer Biotherapy & Radiopharmaceuticals|October 1, 1996
Prognostic markers in interleukin-2 therapyP Lissoni
Annals of the New York Academy of Sciences|March 28, 2001
Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasmsP Lissoni
Pathologie-Biologie|April 21, 2007
Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasmsP Lissoni
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 28, 2002
Is there a role for melatonin in supportive care?P Lissoni
The Cancer Journal From Scientific American|February 11, 1998
Effects of low-dose recombinant interleukin-2 in human malignanciesP Lissoni
The International Journal of Biological Markers|January 1, 1995
Eosinophilia induced by interleukin-2 cancer immunotherapy may be associated with enhanced production of total IgEL Vecchi, P Lissoni
European Urology|June 22, 2000
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatoninP Lissoni, M Mandalà, F Brivio
Cancer Research|September 1, 1994
Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4G J Maestroni, A Conti, P Lissoni
The International Journal of Biological Markers|March 18, 1999
Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerationsP Lissoni, F Rovelli, M Mandalà, et al.
Pageof 29

Showing results (1-10 of 287) with videos related to

Sort By:
Pageof 29
Pathologie-Biologie|April 25, 2007
Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agentP Lissoni
Cancer Biotherapy & Radiopharmaceuticals|October 1, 1996
Prognostic markers in interleukin-2 therapyP Lissoni
Annals of the New York Academy of Sciences|March 28, 2001
Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasmsP Lissoni
Pathologie-Biologie|April 21, 2007
Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasmsP Lissoni
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 28, 2002
Is there a role for melatonin in supportive care?P Lissoni
The Cancer Journal From Scientific American|February 11, 1998
Effects of low-dose recombinant interleukin-2 in human malignanciesP Lissoni
The International Journal of Biological Markers|January 1, 1995
Eosinophilia induced by interleukin-2 cancer immunotherapy may be associated with enhanced production of total IgEL Vecchi, P Lissoni
European Urology|June 22, 2000
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatoninP Lissoni, M Mandalà, F Brivio
Cancer Research|September 1, 1994
Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4G J Maestroni, A Conti, P Lissoni
The International Journal of Biological Markers|March 18, 1999
Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerationsP Lissoni, F Rovelli, M Mandalà, et al.
Pageof 29